DiscoveRx Corporation Signs Agreement with Cosmo Bio Co., Ltd for Drug Discovery Screening Services Representation in Japan
Release date: 2/6/2008
Fremont, CA - February 06, 2008 - DiscoveRx corporation announces the selection of Cosmo Bio Co., Ltd. as a key distributor for the Japanese territory.
"Cosmo Bio's leadership in providing third party drug discovery services to the japanese pharmaceutical and biotech industries and in the distribution of products for life science research is well recognized throughout Japan. We believe that the addition of DiscoveRx Corporation's Selectivity Screen™ GPCR profiling services will significantly benefit Cosmo bio's customers", said Theresa Schaub, Director, Drug Discovery Screening Services at DiscoveRx.
Dr. Haruhisa Sakurai, Director of Cosmo Bio's Drug Discovery Services team, remarked.
"Many drugs relate to their effects via a family of proteins called G-protein-coupled receptors (GPCR). Many industries have focused the development of drugs as one of important targets. To accelerate discovery of more selective screening for disease, we are very excited by the opportunity to offer GPCR Profiling Service by DiscoveRx to Japanese customers."
Additionally, DiscoveRx Corporation continues to add targets to its discovery service offering. The recent introduction of Nuclear Hormone Receptors, Kinases and Orphan GPCRs complement DiscoveRx Corporation's PathHunter™ Cell Based Assays, HitHunter™ Biochemical Assays and screening reagents. Global adoption of the PathHunter™ EFC technology has contributed to discovery of novel compounds worldwide.
About DiscoveRx Corporation
Founded in 2000, DiscoveRx is a privately held, venture-backed company headquartered in Fremont, California, with an additional office in Birmingham, England. The Company pioneered the use of β-galactosidase enzyme fragment complementation in biochemical and cell based assays for discovery research, and holds extensive intellectual property in this area. DiscoveRx is dedicated to the development and commercialization of innovative solutions to study GPCRs, Kinases, NHRs and other major drug target classes. Many of their innovative products have been widely adopted in pharmaceutical and biotech drug screening laboratories worldwide. The company is also recipient of Frost and Sullivan's prestigious 2006 Award for Technology Innovation. This award was given in recognition for successful introduction of PathHunter™ cell based assay platform and the company's overall work on intact and/or lysed cell based assays. For more information on DiscoveRx products, please visit www.discoverx.com.
tel | 510.979.1415 x104
About Cosmo Bio Co., Ltd.
Tokyo-based Cosmo bio Co., Ltd. is a major importer and vendor of reagents, instruments and software for biological research and clinical diagnostics. With approximately 200 sales outlets throughout Japan, Cosmo Bio has over 20 years experience providing expert support to Japan's life science research community. Cosmo Bio's Drug Discovery Services team further provides highly focused technical and business support to the pharmaceutical research community by introducing and facilitating access to the world's top suppliers of drug discovery research services.
Cosmo Bio Co., Ltd.
Haruhisa Sakurai, Ph.D.
Product Communications Department of Cosmo Bio Co., Ltd.
tel | +81(0)3.5632.9616
e | email@example.com